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Cholesterol Dependence of HTLV-I Infection
MATTHEW M. WIELGOSZ,1 DANIEL A. RAUCH,1 KATHRYN S. JONES,2
FRANK W. RUSCETTI,2 and LEE RATNER1
ABSTRACT
Cholesterol-rich plasma membrane microdomains are important for entry of many viruses, including retro-
viruses. Depletion of cholesterol with 2-hydroxypropyl--cyclodextrin inhibits entry of human T cell leuke-
mia virus type I (HTLV-1) and HTLV-I envelope pseudotyped lentivirus particles. Using a soluble fusion pro-
tein of the HTLV-I surface envelope protein with the immunoglobulin Fc domain, the HTLV-I receptor was
found to colocalize with a raft-associated marker and to cluster in specific plasma membrane microdomains.
Depletion of cholesterol did not alter receptor binding activity, suggesting a requirement for cholesterol in a
postbinding virus entry step.
43
INTRODUCTION
THE HUMAN T CELL LEUKEMIA VIRUS TYPE I (HTLV-1) infectsapproximately 10 million people worldwide and causes
adult T cell leukemia lymphoma (ATLL) in 1–10% of infected
individuals.1,2 HTLV-I primarily infects CD4 T cells in vivo,
and in a poorly understood mechanism, causes ATLL, a CD4
lymphoproliferative malignancy.3 The identification of the
HTLV-I receptor would help in the design of a faithful animal
model system that closely resembles the disease manifested in
humans, as well as identification of a potential target for drugs
that block HTLV-I infection. The HTLV-I receptor is widely
expressed on a variety of cells, particularly activated T cells,
and includes a protein component.4–6
The identity of the receptor is unclear, although a recent study
suggests that GLUT-1, a glucose transporter known to mediate
uptake of glucose in a stress-induced manner, binds the HTLV-
I and -II envelope receptor binding domain (RBD) and medi-
ates uptake of HTLV-II pseudotyped particles.7 However, since
these studies utilized cell lines that bind high levels of HTLV
envelope, this work did not address whether GLUT-1 allows
HTLV-I uptake in nonsusceptible target cells. Thus, it is unclear
whether GLUT-1 is functioning as a receptor, a coreceptor, or
an attachment factor for HTLV-I and -II. The role of GLUT-1
in infection by HTLV-I virions has not yet been examined.
Regardless of the identity of the HTLV-I receptor, little is
known about where or how the HTLV-I receptor mediates
HTLV-I infection. For example, are there cofactors that mod-
ulate HTLV-I infection independent of RBD binding, or con-
ditionally with RBD binding to the HTLV-I receptor? Is the
HTLV-I receptor found in discrete microdomains on the plasma
membrane, such as lipid rafts, or is it evenly distributed on the
plasma membrane? Niyogi and Hildreth showed that antibod-
ies that bind lipid raft-associated proteins inhibit HTLV-I syn-
cytium formation and that disruption of lipid rafts disrupts syn-
cytium formation.8 It has also been shown that disruption of
lipid rafts decreases the binding of HTLV-I virions to a T cell
line.9 In addition, biochemical fractionation studies and fluo-
rescence microscopy revealed that GLUT-1 is raft associated,
suggesting that there is spatial interference between these anti-
bodies and virus access to the receptor.10
Lipid rafts are microdomains of the plasma membrane that
contain high concentrations of cholesterol and glycosphingo-
lipids, resulting in insolubility in ice-cold detergent.11 In addi-
tion, lipid rafts contain many different kinds of proteins, par-
ticularly those involved in cell signaling or structural proteins
that may help concentrate signaling proteins, including cave-
olins, flotillins, glycosylphosphatidylinositol (GPI)-linked pro-
teins, low-molecular-weight and heterotrimeric G proteins, src
family kinases, epidermal growth factor (EGF), platelet-derived
growth factor (PDGF), endothelin receptors, the phosphotyro-
sine phosphatase syp, Grb2, Shc, mitogen-activated protein
(MAP) kinase, protein kinase C, and the p85 subunit of PI 3-
kinase.12 It is important to note that not all lipid rafts are iden-
tical, and there is heterogeneity in protein and lipid composi-
tion of lipid rafts from different sources.12
1Departments of Medicine and Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri 63110.
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In this study, we examined the significance of plasma mem-
brane cholesterol in HTLV-I infection and determined whether
or not the HTLV-I receptor associates with lipid rafts. We found
that HTLV-I infection is cholesterol dependent and it is raft as-
sociated as assessed by fluorescent microscopy.
MATERIALS AND METHODS
Reagents
2-Hydroxypropyl--cyclodextrin (2-HPCD), sodium bu-
tyrate, biotin-labeled cholera toxin, goat antibiotin horseradish
peroxidase (HRP) label, murine antibiotin Cy3 conjugate, and
goat anti-rabbit Fc IgG were from Sigma (St. Louis, MO).
Murine anti-human transferrin receptor PE conjugate was from
Calbiochem (La Jolla, CA). Rabbit polyclonal anti-caveolin I
was from Santa Cruz (Santa Cruz, CA). Donkey anti-rabbit HRP
and sheep anti-mouse HRP were from Amersham Life Sciences
(Arlington Heights, IL). All tissue culture media were from
Gibco-BRL (Bethesda, MD) or Washington University (St.
Louis, MO). Plasmids pNL4-3SV40LUCE, pHCMV-G,
pHXADA, pACH-1, and pHTE-1 have been described previ-
ously.6 The plasmids encoding the HTLV-I and avian leukemia
virus subtype A envelope immunoadhesins (HTSU-IgG and
SUA-IgG) were previously described.4 3,3-Dithiobis(sulfosuc-
cinimidylpropionate) (DTSSP) was from Pierce (Rockford, IL).
Cell cultures
HOS, 293T, B5, and MAGI-5 cell lines were maintained in
Dulbecco’s modified Eagle’s medium, 10% heat-inactivated fe-
tal calf serum (HI-FCS), 100 U/ml penicillin, 100 g/ml strep-
tomycin, 1 mM sodium pyruvate, and 1 mM L-glutamine. Pe-
ripheral blood mononuclear cells (PBMCs) were maintained in
RPMI 1640 medium, 10% HI-FCS, 1 mM L-glutamine, 100
U/ml penicillin, 100 g/ml streptomycin, and 50 U/ml inter-
leukin (IL)-2.
Transfections
Transfections were performed with 293T cells at 50–75%
confluency in a T75 culture flask, using 3 l/g of DNA of
TranIT transfection reagent (Mirus Corporation, Madison, WI).
Sixteen hours posttransfection, the DNA was removed, replaced
with fresh medium, and 293T cells were maintained for 1–2
days at 37°C, until supernatant (virus particles) or cell lysate
(immunoadhesin) was isolated.
Virus preparation
Pseudotyped particles were generated as described previ-
ously with some modification.6 293T cells were treated with 20
mM sodium butyrate for 16 hr at 37°C. The medium was re-
moved, and the cells were transfected with 10 g of pNL4-
3SV40LUCE plasmid, an HIV envelope-defective mutant
that encodes the firefly luciferase gene, and 2.5 g of pHCMVG
plasmid for VSV-G enveloped pseudotypes, 10 g pHTE-1
plasmid for HTLV-I enveloped pseudotypes, 10 g pMLV plas-
mid for murine amphotropic leukemia virus (A-MLV) en-
veloped pseudotypes, or 10 g of pHXADA plasmid for HIV
enveloped pseudotypes. To generate wild-type HTLV-I parti-
cles, 15 g of pACH-1 plasmid was used for transfection. To
generate HTLV-I particles pseudotyped with the VSVg enve-
lope, 12 g of pACHEnv and 3 g of pHCMVG were used
for transfection. Two to 3 days posttransfection, the supernatant
and cells were collected via centrifugation at 900  g for 5 min
at 4°C. The viral supernatant was collected and treated with 0.1
mg/ml DNase I with 10 mM MgSO4 for 1 hr at 37°C. The vi-
ral supernatants were passed through 0.22-m syringe filters,
aliquoted, and stored at 80°C.
Infections
Infections were performed after mock or 20 mM 2-HPCD
treatment for 45–60 min at 37°C. Cells were washed with phos-
phate-buffered saline (PBS) before addition of virus particles.
To assess the effect of 2-HPCD on pseudotyped particle in-
fection, 3  104 HOS or MAGI-5 cells per well in 24-well
plates were infected in triplicate with 50 l volumes of HTLV-
I, vesicular stomatitis virus (VSV), A-MLV, or HIV-1 glyco-
protein pseudotyped particles. The cells were incubated at 37°C
for 1 hr, and rocked every 20 min. At 1 hr postinfection, the
inoculae were removed, the cells were washed with PBS, and
0.5 ml of culture media was added. Two days postinfection, the
culture media were removed, and the cells were solubilized with
250 l of LUC lysis buffer (100 mM potassium phosphate, pH
7.8, and 0.2% Triton X-100). Of each sample 200 l was ana-
lyzed using a luminometer. The standard deviation associated











































FIG. 1. 2HPCD inhibits infection of (A) HOS cells and (B)
MAGI-5 cells by a lentivirus particles carrying a luciferase gene
pseudotyped with HTLV-I Env. Cells were treated with () or
without () 2HPCD prior to infection with HTLV-I, VSV,
A-MLV, or HIV-I glycoprotein pseudotyped particles. After 2
days, luciferase activity was measured.
A
B
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To assess the effect of 2-HPCD on wild-type HTLV-I par-
ticle infection, 106 B5 cells were infected with 1 ml of ACH-
1, or VSV-G pseudotyped ACH-1 Env, or heat-inactivated
virus particles. After 1 hr incubation at 37°C, the inoculae were
removed, the cells were washed with PBS, 1 ml of media was
added, and incubated at 37°C for 3 days. The media were re-
moved, B5 cells were washed in PBS, and genomic DNA was
isolated with a QIAamp Blood mini Kit (Qiagen Inc., Valen-
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FIG. 2. Lipid rafts are important for wild type HTLV-I particle entry into B5 cells. B5 cells were pretreated with () or with-
out () 2HPCD, and then infected with HTLV-I particles from ACH or an env mutant of ACH pseudotyped with VSV glyco-
protein, ACH.E-(VSV-G), or heat inactivated particles (HI). After 3 days, DNA was harvested and PCR performed for HTLV-
I 3 LTR or GAPDH sequences. Molecular weight markers were run in the lane designated M, and the size of the amplified DNA
fragments indicated to the right.
FIG. 3. 2-HPCD does not reduce the cell surface expression of the HTLV-I receptor. (A) Fluorescent microscopy was per-
formed and four representative fields each are shown for HOS cells treated with HTSU-Fc, HTSU-Fc following 2HPCD treat-
ment, or SU-FcA. (B) FACS analysis was performed for 293T cells after treatment with HTSU-Fc (solid curve), HTSU-Fc after
2HPCD treatment (dark line), or SU-FcA (light line).
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cia, CA). Three micrograms of genomic DNA per sample was
used to amplify the 3 LTR of HTLV-I using HTLV-I primers
[5-ATCCACGCCGGTTGAGTCGC-3 (forward) and 5-
CACTCAGTCGTGAATGAAAG-3 (reverse)] in 35 amplifi-
cation cycles (94°C for 30 sec, 55°C for 20 sec, and 72°C for
30 sec). Genomic DNA (0.3 g) was used to amplify GAPDH,
using GAPDH-specific primers [5-ACCACAGTCCATGC-
CATCAC-3 (forward) and 5-TCCACCACCCTGTTGCT-
GTA-3 (reverse)] in 35 amplification cycles, as described
above. GAPDH was used as a loading control to monitor the
levels of HTLV-I 3 LTR between samples. PCR reactions were
amplified with REDTAQ (Sigma, St. Louis, MO).
Expression of immunoadhesin proteins
293T cells were transfected with 15 g HTSU-IgG/pSK100
encoding the HTSU-Fc fusion protein or SUA-IgG encoding
the SUA-Fc protein of the avian retrovirus ALSV-A. Two days
posttransfection, the media were removed, the cells were
washed with PBS, and resuspended in ice cold PBS, and soni-
cated twice. Proteinase inhibitor cocktail (Sigma, St. Louis,
MO) was added and lysates were centrifuged at 12,000  g for
1 min. The clarified lysates were pooled, aliquoted, and stored
at 80°C.
FACS analyses
Cells were resuspended in 200 l of HTSU-Fc or SUA-Fc,
incubated at 20°C for 25 min, collected by centrifugation, and
washed with PBS. A 1:25 mixture of FITC-labeled anti-rabbit
IgG antibody in PBS (stock concentration 40 g/ml, Sigma)
with 1% HI-FCS was added and incubated at 4°C for 25 min.
The cells were washed with PBS, incubated at 20°C for 10 min
with 1% paraformaldehyde, and filtered to remove cell clumps.
Fluorescence and confocal microscopy
For fluorescence and confocal microscopy of the HTLV-I
receptor, HOS cells seeded on coverslips were incubated with
200 g/ml HTSU-Fc or SUA-Fc at 20°C for 25 min. The lysates
were removed, the cells were washed with PBS, a 1:25 mix-
ture of FITC-labeled anti-rabbit IgG was added and incubated





FIG. 4. The HTLV-I receptor localizes in GM1-containing lipid rafts. HOS cells were treated with HTSU-Fc and biotin-labeled
cholera toxin and visualized with (A) FITC-labeled anti-rabbit IgG and Cy3-labeled anti-biotin antibody, or (B) biotin-labeled
anti-rabbit IgG and Cy3-labeled antibiotin antibody and FITC-labeled anti-transferrin receptor (TfR) antibody. Representative
fields are shown using filters allowing visualization of only (A) FITC-labeled HTLV-I receptor (top panels), Cy3 labeled GM1
(middle panels), or both (bottom panels), and (B) Cy3 labeled HTLV receptor (left panels), FITC-labeled TfR (middle panels),
or both (right panels).
A
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4% paraformaldehyde, and the coverslips were adhered to mi-
croscope slides with 8 l of 75% glycerol.
To visualize the HTLV-I receptor and ganglioside marker 1
(GM1), HOS cells were incubated with biotin-labeled cholera
toxin (CtB, stock concentration 10 g/ml, Sigma) at a ratio of
1:150 CtB to HTSU-Fc or SUA-Fc lysate, for 25 min at 20°C.
The cells were washed with PBS, treated with 1:100 Cy3-la-
beled anti-biotin antibody (stock concentration 10 g/ml,
Sigma) and 1:25 FITC-labeled antirabbit IgG for 25 min at 4°C,
and processed as described above.
To visualize the HTLV-I and transferrin receptors (TfR),
HOS cells were incubated with 200 g/ml HTSU-Fc lysate for
25 min at 20°C, washed with PBS, then incubated with 1:30
biotin-labeled anti-rabbit IgG antibody (stock concentration 80
g/ml, Sigma, to bind HTSU-Fc) and 1:15 FITC-labeled anti-
TfR antibody (stock concentration 10 g/ml, Santa Cruz, for
25 min at room temperature. The cells were washed with PBS,
treated with 1:100 Cy3-labeled anti-biotin antibody to label
HTSU-Fc with Cy3 for 25 min at 4°C, and processed as de-
scribed above.
RESULTS
Cholesterol is important for HTLV-I envelope-
mediated, pseudotyped particle infection
We have previously shown that HTLV-I requires intact lipid
raft membranes for viral budding from the host plasma mem-
brane.13 In addition, Niyogi and Hildreth found that treatment
of target cells with 2-HPCD, a drug that binds cholesterol and
disrupts lipid rafts, inhibits HTLV-I envelope-mediated syn-
cytium formation.8 Similar findings have been described for
HIV as well.14–16
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FIG. 4. continued
B
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These findings suggested that cell-free HTLV-I infection may
also depend on the integrity of cholesterol-rich lipid rafts. To ex-
amine this issue, HOS cells were cultured with or without cy-
clodextrin, followed by infection with HIV particles encoding the
firefly luciferase gene, pseudotyped with either HTLV-I, A-
MLV, or vesicular stomatitis virus glycoproteins (VSV-G). 
Several different -cyclodextrins, including -cyclodextrin,
methyl--cyclodextrin, and 2-hydroxypropyl--cyclodextrin, 
(2-HPCD) were examined. Each reagent resulted in similar ef-
fects on pseudotyped particle infection, but the solubility and cell
toxicity varied; 2-HPCD was the most soluble and least toxic
agent under the assay conditions. Moreover, 2-HPCD exhibited
a dose–response effect on infection (data not shown).
As shown in Figure 1A, 2-HPCD did not significantly af-
fect VSV-G pseudotyped particle infection in HOS cells. How-
ever, both HTLV-I and A-MLV envelope pseudotyped parti-
cles were sensitive to 2-HPCD treatment, and exhibited a
85–90% reduction in luciferase activity. Similar assays were
also performed with MAGI-5 cells, a HeLa cell line that ex-
presses CD4, CXCR4, and CCR5, with or without prior 2-HP-
CD treatment. In this case, HIV particles pseudotyped with
an R5 HIV-1 envelope were used as an additional control. As
shown in Figure 1B, the effect of 2-HPCD on VSV-G pseudo-
typed particle infection of MAGI-5 cells was not diminished.
In contrast, entry of HTLV-I, A-MLV, and HIV-1 pseudotyped
particles was sensitive to 2-HPCD treatment, and luciferase
activity decreased 80%, 60%, and 25%, respectively. These re-
sults demonstrate that HTLV-I pseudotyped particle infection
depends on cholesterol, and further shows that 2-HPCD does
not negatively affect cell viability since VSV-G particle entry
was not adversely affected by cholesterol extraction.
Cholesterol is important for wild-type HTLV-I particle
entry into B5 cells
The cholesterol dependence of infection of wild-type HTLV-
I particles was also examined. B5 cells, a monkey lung fibroblast
cell line, is the most suitable cell line for efficient replication of
free HTLV-I particles. These cells were treated with 2-HPCD,
and infected with virions from the ACH-1 molecular clone or an
ACH Env virus pseudotyped with VSV-G as a control.17,18 Vi-
ral entry was measured by polymerase chain reaction (PCR) anal-
ysis of newly synthesized DNA. Heat-inactivated (HI) virions
were used as negative controls. As shown in Figure 2, the entry
of wild-type HTLV-I particles into B5 cells was reduced with 2-
HPCD treatment prior to infection, but 2-HPCD treatment had
no effect on the infection of VSV-G pseudotyped HTLV-I en-
velope negative virus. These results show that wild-type HTLV-I
particles require cholesterol for efficient infection.
HTLV-I receptor abundance at the cell surface is not
reduced by 2-HPCD
Since 2-HPCD decreases the ability of HTLV-I particles to
infect susceptible cell lines, we wanted to determine if this ef-
fect was due to a decreased abundance of the HTLV-I receptor
on the surface of cells. Therefore, fluorescent microscopy and
FACS analyses were employed using the HTSU-Fc fusion pro-
tein.4 The HTSU-Fc fusion protein contains the surface pro-
tein of the HTLV-I envelope (SU; gp46) fused to the Fc do-
main of rabbit IgG. This fusion protein has been used to test
for the presence of the HTLV-I receptor on many different cell
lines.4,5 In addition, the SU portion of ALV, fused to the rab-
bit Fc domain of IgG (SUA-Fc), was used as a negative con-
trol to demonstrate the specificity of HTSU-Fc binding. As
shown in Figure 3A, HOS cells incubated with HTSU-Fc, but
not SUA-Fc, were fluorescently labeled with an FITC-conju-
gated antirabbit antibody. The binding of HTSU-Fc to the sur-
face of HOS cells exhibited a speckled pattern, suggesting that
the HTLV-I receptor is located in discrete domains on the sur-
face of HOS cells.
When HOS cells were pretreated with 2-HPCD and then in-
cubated with HTSU-Fc, cell staining for the HTLV-I receptor
did not diminish, but in fact appeared to increase on a subpop-
ulation of cells (Fig. 3A). Most of the HOS cells treated with 2-
HPCD maintained the speckled staining pattern, but 5–20% of
the cells exhibit increased fluorescence, and HTLV-I receptor
staining in these cells appeared diffusely distributed over the cell
surface. Similar results were observed with 293T cells, by FACS
analyses (Fig. 3B). 293T cells that were not treated with drug,
but incubated with HTSU-Fc, exhibited fluorescent staining,
compared to those cells that were treated with the SUA-Fc neg-
ative control. However, this shift was even more pronounced in
a subpopulation of 15% of the cells when 293T cells were treated
with 2-HPCD before HTSU-Fc incubation.
The HTLV-I receptor colocalizes with 
lipid rafts markers
Since antibodies to raft-associated proteins inhibit HTLV-I
envelope-mediated syncytium formation,14 it was logical to de-
termine if the HTLV-I receptor exhibited a distribution similar
to that of lipid raft marker ganglioside marker 1 (GM1). As
shown in Figure 4, the HTLV-I receptor colocalized with GM1,
as assessed by biotin-labeled cholera toxin binding and Cy3-la-
beled antibiotin antibody. In contrast, the localization of the
HTLV-I receptor and the transferrin receptor (TfR), a nonlipid
raft marker, was distinct and did not overlap. These results in-
dicate that a significant population of the HTLV-I receptor re-
sides in GM1-containing lipid rafts.
DISCUSSION
Lipid rafts, which are enriched in cholesterol and sphin-
golipids, play a critical role in the lateral organization and mo-
bility of plasma membrane constituents.11,19,20 Rafts are im-
portant in cell signaling, including activation of tyrosine
kinases, NFB activation, and interleukin expression.21–24 Sev-
eral viruses use lipid rafts in one or more aspects of their repli-
cation cycle,25–28 including virus assembly,14,29–35 budding36,37
fusion,38 and virus entry.39–44 Receptors for HIV, murine leu-
kemia virus, herpes simplex virus, pseudorabies virus, and 
coxsackie viruses are raft associated.16,45–47 Moreover, viral
docking proteins, such as DC-SIGN, are also associated with
rafts.48
The current studies demonstrate that rafts are important for
entry of HTLV-I and HTLV-I envelope pseudotyped particles
(Figs. 1 and 2). Moreover, the HTLV-I receptor is associated
with rafts (Fig. 4). However, envelope protein binding to the
receptor is not disrupted by cholesterol depletion (Fig. 3). One
explanation for these results is that receptor binding does not
WIELGOSZ ET AL.48
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require rafts, but once bound, lateral mobility into rafts is re-
quired for subsequent entry events.
Several potential explanations can be proposed for these find-
ings. (1) The HTLV-I receptor may require a cholesterol-rich
domain to allow appropriate conformational changes of the en-
velope protein to occur to become fusion competent. This ex-
planation was offered to explain the role of cholesterol in HIV-
1 entry to permit the HIV-1 gp41 transmembrane protein to
form “stalk intermediates” required for fusion.49 (2) Alterna-
tively, an HTLV-I coreceptor, required for virus entry, may be
raft associated. (3) A third possibility is that raft-association
may be required to exclude inhibitors of virus entry. (4) An-
other possibility is that raft-associated components may allow
virus entry to avoid the degradative endocytic pathways, and
direct virus uptake to a recycling endosomes low in protease
activity, as described for avian leukemia virus subtype A en-
try.50,51 (5) Another consideration is that virus targeting to rafts
during entry may be required for a signaling event necessary
for the virus uptake. One example of this phenomenon is that
cholesterol depletion blocks the ability of HIV-1 coreceptors
CCR5 and CXCR4 to mediate activation of G proteins, as well
as gp120 surface envelope protein activation of MAPK.52,53
GLUT-1 and neuropilin-1 have been proposed as HTLV re-
ceptors, and both proteins have also been reported to be raft as-
sociated.7,9,54 However, further work is required to define the
role of each of these proteins in HTLV entry. Infection by free
HTLV-I virions is not efficient. Recently, new observations
have identified specialized contacts between infected and un-
infected cells, designated viral synapses. Viral synapses have
been shown to be important in facilitating HTLV-I transmis-
sion.55 Based on their similarity to immunological synapses,
these domains are likely enriched in rafts. The current work
provides new information regarding the role of rafts that is rel-
evant to understanding the mechanism of HTLV entry.
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